Provided by Tiger Trade Technology Pte. Ltd.

Vanda Pharmaceuticals

5.28
-0.1000-1.86%
Post-market: 5.26-0.0200-0.38%19:36 EDT
Volume:656.79K
Turnover:3.50M
Market Cap:319.24M
PE:-1.14
High:5.42
Open:5.42
Low:5.27
Close:5.38
52wk High:9.94
52wk Low:4.27
Shares:60.46M
Float Shares:51.04M
Volume Ratio:0.72
T/O Rate:1.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.6291
EPS(LYR):-3.7413
ROE:-77.81%
ROA:-22.38%
PB:1.45
PE(LYR):-1.41

Loading ...

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), Vanda (VNDA) and AbCellera Biologics (ABCL)

TIPRANKS
·
Aug 10

B. Riley Adjusts Vanda Pharmaceuticals Price Target to $12 From $17, Maintains Buy Rating

MT Newswires Live
·
Aug 10

Vanda Pharmaceuticals is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 10

Vanda (VNDA) Gets a Buy from Cantor Fitzgerald

TIPRANKS
·
Aug 08

Praxis Precision Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 06

Aclaris Therapeutics Q2 Revenue Beats Analyst Estimates

Reuters
·
Aug 06

Vanda Pharmaceuticals Balances Strong Growth With Rising Losses

TIPRANKS
·
Aug 06

Vanda Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Vanda Pharmaceuticals Q2 Loss Widens on Lower Sales, Higher Costs

Reuters
·
Aug 06

Vanda Pharma Q2 EPS $(1.04) Misses $(0.59) Estimate, Sales $50.529M Miss $61.925M Estimate

Benzinga Earnings
·
Aug 06

Vanda Q2 GAAP Net Loss Widens to $62.5 Million; Revenue Falls 3.9% to $50.53 Million

Reuters
·
Aug 06

Vanda Pharmaceuticals Q2 EPS USD -1.04

THOMSON REUTERS
·
Aug 06

Vanda Pharmaceuticals Inc Expected to Post a Loss of 59 Cents a Share - Earnings Preview

Reuters
·
Aug 04

Vanda Pharmaceuticals Schedules Q2 Earnings Release and Conference Call

Reuters
·
Jul 30

Analysts Are Bullish on Top Healthcare Stocks: Vanda (VNDA), Celldex (CLDX)

TIPRANKS
·
Jul 22

Vanda Reports Positive Opinion for Imsidolimab Orphan Drug Label

MT Newswires Live
·
Jul 17

Vanda announces EMA positive opinion for orphan drug designation of Imsidolimab

TIPRANKS
·
Jul 17

Vanda Says EMA Panel Backs Orphan Drug Designation for Imsidolimab in Generalized Pustular Psoriasis

Reuters
·
Jul 17

Vanda Pharmaceuticals - Imsidolimab Bla for Gpp Under FDA Review with Target Action Date December 12, 2026

THOMSON REUTERS
·
Jul 17

Vanda Pharmaceuticals - Announces Ema Positive Opinion for Orphan Drug Designation of Imsidolimab for Gpp

THOMSON REUTERS
·
Jul 17